首页 | 本学科首页   官方微博 | 高级检索  
检索        

穴位埋线治疗实验性结肠炎大鼠的分子机制
作者姓名:Zhang XY  Shen L  Fan H  Liao Y  Liang L
作者单位:华中科技大学同济医学院附属协和医院中西医结合科,湖北武汉,430022
摘    要:目的:探讨穴位埋线治疗实验性结肠炎大鼠的作用效应及作用机制.方法:将18只SD大鼠随机分为3组:正常对照组、模型组、穴位埋线组,每组6只.除正常对照组未行造模外,其余两组大鼠均采用三硝基苯磺酸(TNBS)造模.模型组不予干预,正常饮食.穴位埋线组于“上巨虚”“天枢”“大肠俞”处进行穴位埋线治疗.治疗15 d后观察大鼠的腹泻、便血症状和结肠病理组织学改变,用免疫组化染色法观察大鼠结肠组织白细胞介素17(IL-17)、β2肾上腺素受体(β2AR)、核因子κcBp65(NF-κBp65)的表达;用Western blot法检测大鼠脾淋巴细胞β2AR和NF-κBp65蛋白的表达.结果:穴位埋线组的大鼠腹泻、黏液脓血便症状得到较快控制,大鼠结肠黏膜组织损伤明显改善.大鼠脾淋巴细胞NF-κcBp65的表达,与正常组(86.22±8.09)相比,模型组(249.70±13.66)的表达增多(P<0.01);与模型组相比,穴位埋线组(219.02±7.42)的表达减少(P<0.01).大鼠脾淋巴细胞β2AR的表达,与正常组(957.45±171.56)相比,模型组(594.97±173.22)的表达减少(P<0.01);与模型组相比,穴位埋线组(1335.93±244.34)的表达增多(P<0.01).模型组大鼠结肠黏膜组织中IL-17的表达增多,而穴位埋线组中IL-17的表达减少.结论:穴位埋线“上巨虚”“天枢”“大肠俞”治疗实验性结肠炎有明显效果,其作用机制可能是通过调节IL-17、β2AR、NF-κcBp65的表达,发挥其治疗作用.

关 键 词:结肠炎  穴位埋线  β2肾上腺素受体  核因子κBp65  白细胞介素17

Molecular mechanism of acupoint catgut-embedding for experimental colitis in rats
Zhang XY,Shen L,Fan H,Liao Y,Liang L.Molecular mechanism of acupoint catgut-embedding for experimental colitis in rats[J].Chinese Acupuncture & Moxibustion,2011,31(10):913-918.
Authors:Zhang Xia-Yi  Shen Lin  Fan Heng  Liao Yi  Liang Li
Institution:ZHANG Xia-yi,SHEN Lin,FAN Heng,LIAO Yi,LIANG Li(Department of Integrated Chinese and Western Medicine,Union Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China)
Abstract:Objective To explore the effect and its mechanism of acupoint catgut-embedding for experimental colitis in rats.Methods Eighteen SD rats were randomly divided into a normal control(NC) group,a model(MO) group and a acupoint catgut-embedding(AC) group,6 rats in each group.Animals in MO group and AC group were treated by trinitro-benzene-sulfonic acid(TNBS) to establish model with colitis.No other treatment was given to the rats in MO group,but acupoint catgut-embedding was implanted at Shangjuxu(ST 37),Tians...
Keywords:
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号